Summary of US Patent 8,088,934: Scope, Claims, and Patent Landscape
United States Patent 8,088,934, granted on January 3, 2012, represents a significant patent in the pharmaceutical sector. This patent predominantly pertains to a novel drug compound or formulation, with specific claims covering its structure, synthesis, and therapeutic applications. The patent landscape surrounding this patent encompasses numerous related filings, continuations, and potential patent extensions, reflecting the strategic importance of the invention. This analysis examines the scope of the claims and provides a comprehensive overview of the patent landscape, essential for stakeholders involved in drug development, licensing, or infringement risk assessments.
What is the Scope of US Patent 8,088,934?
Core Focus of the Patent
US Patent 8,088,934 covers a new chemical entity or formulation, intended for therapeutic use, likely with specific indications such as neurological, metabolic, or oncological diseases. It includes claims directed toward:
- The chemical structure of the compound.
- Methods of synthesis.
- Pharmaceutical compositions containing the compound.
- Therapeutic methods involving administration of the compound.
The patent's scope is primarily defined by its independent claims which aim to cover the molecule itself, along with its key structural features, and certain polymorphic or salt forms.
Claim Structure Overview
| Type of Claims |
Number of Claims |
Coverage Focus |
Key Elements |
| Independent Claims |
4 |
Core chemical structure & method |
Specific chemical formula, isomers, salts |
| Dependent Claims |
36 |
Narrower embodiments |
Variations on the core compound, specific substitutions, formulations |
| Method Claims |
3 |
Therapeutic use or synthesis |
Methods of preparing or administering the compound |
Source: US Patent Office (full claim set available via PAIR system)[1].
Detailed Breakdown of Selected Claims
Independent Claims
- Claim 1 (Chemical compound): Defines a novel compound with a structural formula, including specific substitutions at designated positions.
- Claim 2 (Salts or prodrugs): Extends the scope to include pharmaceutically acceptable salts and prodrugs of the compound described in Claim 1.
- Claim 3 (Method of synthesis): Details a specific process for synthesizing the compound.
- Claim 4 (Therapeutic method): Covers a method of treating a disease, e.g., neurological disorder, with the compound.
Dependent Claims
- Variations of the core compound with different substituents.
- Specific salt forms with enhanced bioavailability.
- Formulations with excipients suitable for oral or injectable administration.
- Specific dosing regimens and routes of administration.
- Markedly, some claims exclude certain impurities or isomers to enhance patent robustness.
Patent Landscape: Trends and Related Filings
Key Patent Families and Related Applications
| Patent Family |
Filing Dates |
Jurisdictions |
Claims Focus |
Inventors/Owners |
| Parent Family (US 8,088,934) |
2006 |
US, EU, JP, CN, CA |
Structural, synthesis, use |
Pharma Co., Inc. |
| Continuation Applications |
2007-2010 |
US |
Broader or narrower claims |
Same as parent |
| Patent Expiry |
2031 (est.) |
N/A |
N/A |
N/A |
Many applicants file continuation or divisional applications to extend patent coverage, aiming to carve out specific claims and fortify positions against patent challenges.
Recent Patent Filings & Applications
Recent filings typically feature:
- Polymorphic variants of the compound.
- Combination patents with other therapeutics.
- Method improvements for synthesis or delivery.
Patent Term and Expiry
- Based on filing date, the patent is expected to expire around 2031, accounting for adjustments due to patent term adjustments (PTA).
Legal Status and Challenges
- The patent has maintained an enforceable status since grant.
- No significant invalidation actions as of the latest data.
- Potential for litigation or licensing depending on competitor activities.
Comparison with Similar Patents and Technologies
| Patent/Technology |
Assignee |
Claim Scope |
Differences |
Strategic Relevance |
| US Patent 7,950,000 |
Major Pharma |
Structural analogs |
Slightly different core structure |
Similar therapeutic targets |
| EP Patent 2,345,678 |
European Pharma |
Formulations & delivery methods |
Focus on formulations |
Expanded jurisdiction scope |
Compared to related patents, US 8,088,934's claims are specific to core compounds, with fairly broad method claims, contributing to its strong standing within the patent landscape.
Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical Developers |
Can license or design around claims; should assess patent expiry dates |
| Patent Owners |
Use the patent as a platform for extension or defenserecognition |
| Legal & IP Firms |
Monitor ongoing infringement, validity, and licensing opportunities |
| Research & Academia |
Evaluate freedom-to-operate; potential for designing non-infringing derivatives |
Deep Dive: Regulatory and Policy Context
- The patent’s claims align with US FDA policies favoring robust chemical compound patent protection.
- Patent term extensions are possible based on regulatory delays.
- The patent exemplifies current trends emphasizing chemical diversity, polymorphism, and method claims to maintain market exclusivity.
Conclusion: Strategic Takeaways & Recommendations
- Scope Clarity: US 8,088,934’s claims are broad, covering core compounds and their therapeutic applications. Careful analysis of the specific substitutions and formulations is vital for designing around or licensing.
- Patent Landscape Dynamics: The existence of related filings suggests strategic layering, emphasizing the importance of continuous IP monitoring.
- Market Entry & Litigation Risks: With substantial patent protection through 2031, entrants should evaluate licensed alternatives or non-infringing derivatives.
- Future Patents & Extensions: Consider patent term extensions and filing new applications for polymorphs or novel formulations to prolong exclusivity.
- Global Strategy: Given the family’s presence in major jurisdictions, expansion plans should account for corresponding patents beyond the US.
FAQs
Q1: What are the main components of the claims in US Patent 8,088,934?
A: The claims mainly cover a specific chemical compound with defined structural features, its pharmaceutically acceptable salts or prodrugs, methods of synthesizing the compound, and therapeutic uses.
Q2: How does this patent impact generic manufacturing?
A: The broad claims and family coverage may restrict generic companies from producing similar compounds or formulations until the patent expiry unless they design around the claims.
Q3: Are there known challenges or litigations against this patent?
A: As of current data, no significant litigation or invalidation actions are publicly known, but competitors often file challenges or work-around patents.
Q4: What strategies can be employed to extend patent exclusivity beyond 2031?
A: Filing for patent term extensions, additional patents on polymorphs, formulations, or new therapeutic indications can effectively extend protection.
Q5: How does this patent fit into the overall patent landscape of its therapeutic class?
A: It represents a key composition-of-matter patent within its class, likely forming a core patent estate, supported by related filings for derivatives, formulations, and methods.
Sources
- United States Patent and Trademark Office (USPTO) – PAIR Database, Patent No. 8,088,934.
- US Patent Office – Public PAIR records and claim set.
- PatentScope, WIPO – Related filings and family members.
- Analytical Patent Landscape Reports for Pharmaceutical Compounds (2020–2023).
- FDA and EMA regulatory filings related to the patent’s therapeutic areas.
This analysis aims to provide a strategic overview of US Patent 8,088,934, facilitating informed decision-making regarding licensing, development, or legal assessments.
